ERBB2 and cancer: H&N cancers comprised 140 patients (3-4%), primarily secretory salivary carcinoma in NTRK trials (n = 12-20), thyroid carcinoma in BRAF (<i>n</i> = 36) and RET (<i>n</i> = 45) programs, and rare HER2-positive salivary duct carcinomas.